Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda San Francisco (TSF) and Pieris have entered into an agreement, under which Pieris will use its Anticalin scaffold technology to deliver protein therapeutic candidates to Takeda.
Subscribe to our email newsletter
Anticalins are recombinantly engineered lipocalins, endogenous low-molecular weight human proteins that naturally bind, store and transport a wide spectrum of molecules.
The tie up includes an option of expansion following the delivery of a successful candidate to Takeda.
Further deal terms and financial details were not disclosed.
TSF president and CSO Mary Haak-Frendsch said that Pieris’ Anticalin technology complements their existing capabilities by enabling a novel approach to targets where differentiation from traditional antibodies is required.